Share Price and Basic Stock Data
Last Updated: October 22, 2025, 4:09 am
| PEG Ratio | 17.53 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Jubilant Pharmova Ltd operates within the pharmaceuticals industry, focusing on a diverse portfolio that includes contract manufacturing and drug development. The company’s stock price stood at ₹1,144, with a market capitalization of ₹18,219 Cr. Over the past few quarters, sales have shown a consistent upward trend, rising from ₹1,452 Cr in June 2022 to ₹1,759 Cr by March 2024, with TTM sales recorded at ₹7,404 Cr. This growth trajectory highlights the company’s ability to expand its market share and product offerings, despite facing challenges in certain periods, such as the dip in sales to ₹1,552 Cr in December 2022. The operating profit margin (OPM) fluctuated over these quarters, with a notable increase to 18% in March 2025, reflecting improving operational efficiency. Overall, the revenue growth and shifting sales figures indicate a dynamic business environment, with the company adapting to market demands and leveraging its capabilities effectively.
Profitability and Efficiency Metrics
Jubilant Pharmova’s profitability metrics reveal a complex picture of its financial health. The net profit for the fiscal year ending March 2025 stood at ₹836 Cr, a significant recovery from a loss of ₹65 Cr in March 2023. The company’s earnings per share (EPS) also improved dramatically, reaching ₹52.99 in March 2025, compared to a loss per share of ₹3.83 in the previous year. The interest coverage ratio (ICR) improved to 5.12x, indicating that the company can comfortably cover its interest expenses, a positive sign for creditors and investors alike. However, the return on equity (ROE) remained moderate at 9.55%, suggesting that while profitability is recovering, it still lags behind sector leaders. The operating profit margin, which fluctuated but reached 18% in March 2025, is a strong indicator of the company’s operational efficiency, positioning it favorably within the industry context.
Balance Sheet Strength and Financial Ratios
Jubilant Pharmova’s balance sheet reflects a reasonable leverage situation, with total borrowings reported at ₹2,731 Cr against reserves of ₹6,239 Cr. The debt-to-equity ratio stood at 0.38, indicating a conservative approach to leveraging, which is below the typical sector range. The current ratio of 1.65 suggests that the company maintains adequate liquidity to meet its short-term liabilities. Additionally, the price-to-book value (P/BV) ratio was recorded at 2.25x, indicating a relatively high valuation compared to its book value, which was ₹395.88 per share as of March 2025. The company has improved its cash conversion cycle (CCC) to 65 days, showcasing enhanced efficiency in managing working capital. These financial ratios collectively underscore a stable and improving financial position, essential for sustaining operational growth and navigating market challenges.
Shareholding Pattern and Investor Confidence
As of June 2025, Jubilant Pharmova’s shareholding pattern indicates a diverse ownership structure, with promoters holding 47.67% of the shares, down from 50.67% in earlier periods. Foreign institutional investors (FIIs) accounted for 17.40%, while domestic institutional investors (DIIs) held 9.52%. The public’s stake stood at 24.83%, reflecting a balanced distribution of ownership that can enhance market stability and investor confidence. The number of shareholders increased to 99,673, indicating growing interest in the company. However, the decline in promoter holdings could raise concerns regarding commitment and control. The recent performance recovery and increasing institutional interest may bolster investor confidence and attract further investments, essential for future growth trajectories.
Outlook, Risks, and Final Insight
Looking ahead, Jubilant Pharmova faces both opportunities and risks. The recovery in profitability and operational efficiency suggests a positive outlook for the company, particularly if it can maintain its revenue growth and improve margins. However, risks such as fluctuating raw material costs, regulatory challenges, and competitive pressures in the pharmaceutical sector could impact performance. Additionally, the company’s reliance on a limited number of product lines may expose it to market volatility. Strengths such as a solid balance sheet and improving operational metrics provide a buffer against these risks. In a scenario where the company successfully diversifies its product offerings and navigates regulatory landscapes effectively, it could see substantial growth. Conversely, failure to address these challenges could hinder its recovery and growth potential, necessitating strategic focus and agility in operations.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Jubilant Pharmova Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,993 Cr. | 458 | 465/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 38.1 Cr. | 51.3 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.9 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,038.24 Cr | 1,197.65 | 50.64 | 194.07 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,452 | 1,600 | 1,552 | 1,678 | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 |
| Expenses | 1,259 | 1,384 | 1,408 | 1,459 | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 |
| Operating Profit | 192 | 216 | 144 | 219 | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 |
| OPM % | 13% | 14% | 9% | 13% | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% |
| Other Income | 11 | -44 | 10 | 21 | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 |
| Interest | 40 | 42 | 51 | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 |
| Depreciation | 95 | 94 | 94 | 271 | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 |
| Profit before tax | 69 | 36 | 9 | -86 | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 |
| Tax % | 32% | 87% | 285% | 16% | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% |
| Net Profit | 47 | 5 | -16 | -100 | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 |
| EPS in Rs | 2.96 | 0.34 | -0.98 | -6.15 | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 |
Last Updated: August 1, 2025, 6:40 pm
Below is a detailed analysis of the quarterly data for Jubilant Pharmova Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,901.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,929.00 Cr. (Mar 2025) to 1,901.00 Cr., marking a decrease of 28.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,611.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,584.00 Cr. (Mar 2025) to 1,611.00 Cr., marking an increase of 27.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 290.00 Cr.. The value appears to be declining and may need further review. It has decreased from 345.00 Cr. (Mar 2025) to 290.00 Cr., marking a decrease of 55.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 15.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 53.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 98.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 206.00 Cr. (Mar 2025) to 154.00 Cr., marking a decrease of 52.00 Cr..
- For Tax %, as of Jun 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Mar 2025) to 34.00%, marking an increase of 7.00%.
- For Net Profit, as of Jun 2025, the value is 102.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2025) to 102.00 Cr., marking a decrease of 49.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.46. The value appears to be declining and may need further review. It has decreased from 9.64 (Mar 2025) to 6.46, marking a decrease of 3.18.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,762 | 5,751 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 7,404 |
| Expenses | 4,763 | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 | 6,192 |
| Operating Profit | 999 | 610 | 1,256 | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,211 |
| OPM % | 17% | 11% | 22% | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% | 16% | 16% |
| Other Income | -173 | 86 | 4 | 19 | 36 | -249 | 225 | 263 | 8 | -9 | -76 | 416 | 18 |
| Interest | 337 | 368 | 371 | 341 | 284 | 220 | 200 | 184 | 145 | 188 | 272 | 240 | 218 |
| Depreciation | 281 | 288 | 347 | 291 | 415 | 371 | 340 | 349 | 382 | 554 | 382 | 369 | 376 |
| Profit before tax | 207 | 40 | 542 | 738 | 859 | 904 | 1,233 | 1,133 | 630 | 28 | 170 | 981 | 635 |
| Tax % | 34% | 200% | 29% | 22% | 26% | 36% | 27% | 26% | 34% | 333% | 57% | 15% | |
| Net Profit | 138 | -40 | 387 | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 457 |
| EPS in Rs | 6.84 | -3.63 | 24.60 | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 28.88 |
| Dividend Payout % | 43% | -83% | 12% | 8% | 7% | 12% | 9% | 10% | 19% | -130% | 102% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -128.99% | 1067.50% | 48.58% | 10.26% | -8.99% | 55.63% | -6.90% | -50.60% | -115.74% | 212.31% | 1045.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1196.49% | -1018.92% | -38.32% | -19.25% | 64.62% | -62.54% | -43.69% | -65.14% | 328.05% | 832.90% |
Jubilant Pharmova Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 4% |
| 3 Years: | 6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | -10% |
| 3 Years: | 10% |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 8% |
| 3 Years: | 48% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 1% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 8:35 am
Balance Sheet
Last Updated: August 11, 2025, 2:10 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 2,611 | 2,438 | 2,951 | 3,420 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 | 6,239 |
| Borrowings | 4,395 | 4,793 | 4,493 | 4,045 | 3,469 | 4,840 | 4,808 | 2,830 | 3,192 | 3,677 | 3,664 | 2,731 |
| Other Liabilities | 1,842 | 1,372 | 1,280 | 1,417 | 1,902 | 1,670 | 1,898 | 1,192 | 1,319 | 1,853 | 2,240 | 3,598 |
| Total Liabilities | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 |
| Fixed Assets | 5,099 | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 | 5,176 |
| CWIP | 472 | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 | 3,630 |
| Investments | 34 | 40 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 |
| Other Assets | 3,259 | 3,071 | 2,939 | 3,006 | 3,262 | 4,654 | 5,133 | 3,017 | 3,631 | 3,928 | 4,101 | 3,735 |
| Total Assets | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 |
Below is a detailed analysis of the balance sheet data for Jubilant Pharmova Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
- For Reserves, as of Mar 2025, the value is 6,239.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,418.00 Cr. (Mar 2024) to 6,239.00 Cr., marking an increase of 821.00 Cr..
- For Borrowings, as of Mar 2025, the value is 2,731.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 3,664.00 Cr. (Mar 2024) to 2,731.00 Cr., marking a decrease of 933.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 3,598.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,240.00 Cr. (Mar 2024) to 3,598.00 Cr., marking an increase of 1,358.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 12,584.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,338.00 Cr. (Mar 2024) to 12,584.00 Cr., marking an increase of 1,246.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 5,176.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,091.00 Cr. (Mar 2024) to 5,176.00 Cr., marking an increase of 85.00 Cr..
- For CWIP, as of Mar 2025, the value is 3,630.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,103.00 Cr. (Mar 2024) to 3,630.00 Cr., marking an increase of 1,527.00 Cr..
- For Investments, as of Mar 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2024) to 44.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Mar 2025, the value is 3,735.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,101.00 Cr. (Mar 2024) to 3,735.00 Cr., marking a decrease of 366.00 Cr..
- For Total Assets, as of Mar 2025, the value is 12,584.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,338.00 Cr. (Mar 2024) to 12,584.00 Cr., marking an increase of 1,246.00 Cr..
Notably, the Reserves (6,239.00 Cr.) exceed the Borrowings (2,731.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 995.00 | 606.00 | -3.00 | -3.00 | -2.00 | -3.00 | -3.00 | -1.00 | -2.00 | 776.00 | 898.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 52 | 60 | 63 | 55 | 51 | 79 | 49 | 55 | 56 | 50 | 45 |
| Inventory Days | 200 | 169 | 207 | 223 | 177 | 147 | 463 | 268 | 308 | 268 | 220 | 178 |
| Days Payable | 107 | 99 | 106 | 137 | 145 | 106 | 273 | 124 | 139 | 160 | 146 | 158 |
| Cash Conversion Cycle | 144 | 122 | 162 | 149 | 87 | 92 | 268 | 194 | 224 | 165 | 124 | 65 |
| Working Capital Days | -92 | 12 | 4 | 50 | 45 | 45 | 62 | 74 | 56 | 57 | 56 | 16 |
| ROCE % | 11% | 6% | 13% | 15% | 15% | 16% | 15% | 12% | 10% | 3% | 7% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund | 550,339 | 0.37 | 20.61 | 550,339 | 2025-04-22 15:56:56 | 0% |
| Nippon India Nifty Smallcap 250 Index Fund | 46,210 | 0.24 | 1.73 | 46,210 | 2025-04-22 17:25:29 | 0% |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 29,012 | 0.24 | 1.09 | 29,012 | 2025-04-22 17:25:29 | 0% |
| SBI Nifty Smallcap 250 Index Fund | 21,292 | 0.24 | 0.8 | 21,292 | 2025-04-22 15:56:56 | 0% |
| Motilal Oswal Nifty 500 Index Fund | 3,170 | 0.02 | 0.12 | 3,170 | 2025-04-22 15:56:56 | 0% |
| Edelweiss Nifty Smallcap 250 Index Fund | 980 | 0.24 | 0.04 | 980 | 2025-04-22 15:56:56 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 827 | 0.38 | 0.03 | 827 | 2025-04-22 17:25:29 | 0% |
| Groww Nifty Total Market Index Fund | 178 | 0.02 | 0.01 | 178 | 2025-04-22 17:25:29 | 0% |
| Motilal Oswal Nifty 500 ETF | 139 | 0.02 | 0.01 | 139 | 2025-04-22 15:56:56 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 52.99 | 4.87 | -3.83 | 26.00 | 52.48 |
| Diluted EPS (Rs.) | 52.99 | 4.86 | -3.83 | 26.00 | 52.48 |
| Cash EPS (Rs.) | 76.29 | 27.25 | 29.98 | 50.55 | 73.70 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Revenue From Operations / Share (Rs.) | 457.88 | 424.23 | 394.85 | 385.08 | 383.10 |
| PBDIT / Share (Rs.) | 77.88 | 61.36 | 51.20 | 73.35 | 88.83 |
| PBIT / Share (Rs.) | 54.55 | 37.19 | 16.38 | 49.37 | 66.91 |
| PBT / Share (Rs.) | 62.09 | 9.27 | 0.97 | 40.23 | 54.01 |
| Net Profit / Share (Rs.) | 52.96 | 3.08 | -4.85 | 26.57 | 51.78 |
| NP After MI And SOA / Share (Rs.) | 53.13 | 4.88 | -3.83 | 26.00 | 52.51 |
| PBDIT Margin (%) | 17.00 | 14.46 | 12.96 | 19.04 | 23.18 |
| PBIT Margin (%) | 11.91 | 8.76 | 4.14 | 12.82 | 17.46 |
| PBT Margin (%) | 13.56 | 2.18 | 0.24 | 10.44 | 14.09 |
| Net Profit Margin (%) | 11.56 | 0.72 | -1.22 | 6.90 | 13.51 |
| NP After MI And SOA Margin (%) | 11.60 | 1.15 | -0.97 | 6.75 | 13.70 |
| Return on Networth / Equity (%) | 13.41 | 1.41 | -1.12 | 7.78 | 17.62 |
| Return on Capital Employeed (%) | 8.13 | 6.08 | 2.77 | 9.35 | 13.53 |
| Return On Assets (%) | 6.58 | 0.66 | -0.54 | 4.14 | 9.37 |
| Long Term Debt / Equity (X) | 0.34 | 0.58 | 0.57 | 0.46 | 0.54 |
| Total Debt / Equity (X) | 0.38 | 0.62 | 0.63 | 0.55 | 0.54 |
| Asset Turnover Ratio (%) | 0.59 | 0.59 | 0.59 | 0.01 | 0.37 |
| Current Ratio (X) | 1.65 | 2.05 | 2.12 | 2.20 | 2.81 |
| Quick Ratio (X) | 1.13 | 1.37 | 1.34 | 1.42 | 1.74 |
| Inventory Turnover Ratio (X) | 5.98 | 1.36 | 1.26 | 0.00 | 1.44 |
| Dividend Payout Ratio (NP) (%) | 9.48 | 103.24 | -130.60 | 19.23 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.58 | 17.34 | 16.15 | 10.00 | 0.00 |
| Earning Retention Ratio (%) | 90.52 | -3.24 | 230.60 | 80.77 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.42 | 82.66 | 83.85 | 90.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.12 | 3.56 | 4.33 | 8.03 | 7.68 |
| Interest Coverage Ratio (Post Tax) (X) | 2.99 | 1.80 | 0.89 | 3.91 | 4.17 |
| Enterprise Value (Cr.) | 15436.46 | 11426.80 | 6827.69 | 8114.60 | 12743.97 |
| EV / Net Operating Revenue (X) | 2.13 | 1.70 | 1.09 | 1.32 | 2.09 |
| EV / EBITDA (X) | 12.54 | 11.79 | 8.38 | 6.95 | 9.01 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| Retention Ratios (%) | 90.51 | -3.24 | 230.60 | 80.76 | 0.00 |
| Price / BV (X) | 2.25 | 1.65 | 0.82 | 1.16 | 2.28 |
| Price / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| EarningsYield | 0.05 | 0.01 | -0.01 | 0.06 | 0.07 |
After reviewing the key financial ratios for Jubilant Pharmova Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.87 (Mar 24) to 52.99, marking an increase of 48.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.86 (Mar 24) to 52.99, marking an increase of 48.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 76.29. This value is within the healthy range. It has increased from 27.25 (Mar 24) to 76.29, marking an increase of 49.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 457.88. It has increased from 424.23 (Mar 24) to 457.88, marking an increase of 33.65.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 77.88. This value is within the healthy range. It has increased from 61.36 (Mar 24) to 77.88, marking an increase of 16.52.
- For PBIT / Share (Rs.), as of Mar 25, the value is 54.55. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 54.55, marking an increase of 17.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.09. This value is within the healthy range. It has increased from 9.27 (Mar 24) to 62.09, marking an increase of 52.82.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 52.96. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 52.96, marking an increase of 49.88.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 53.13. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 53.13, marking an increase of 48.25.
- For PBDIT Margin (%), as of Mar 25, the value is 17.00. This value is within the healthy range. It has increased from 14.46 (Mar 24) to 17.00, marking an increase of 2.54.
- For PBIT Margin (%), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 8.76 (Mar 24) to 11.91, marking an increase of 3.15.
- For PBT Margin (%), as of Mar 25, the value is 13.56. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 13.56, marking an increase of 11.38.
- For Net Profit Margin (%), as of Mar 25, the value is 11.56. This value exceeds the healthy maximum of 10. It has increased from 0.72 (Mar 24) to 11.56, marking an increase of 10.84.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 11.60, marking an increase of 10.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.41. This value is below the healthy minimum of 15. It has increased from 1.41 (Mar 24) to 13.41, marking an increase of 12.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.13. This value is below the healthy minimum of 10. It has increased from 6.08 (Mar 24) to 8.13, marking an increase of 2.05.
- For Return On Assets (%), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 0.66 (Mar 24) to 6.58, marking an increase of 5.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.58 (Mar 24) to 0.34, marking a decrease of 0.24.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.38, marking a decrease of 0.24.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has decreased from 2.05 (Mar 24) to 1.65, marking a decrease of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.13, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 1.36 (Mar 24) to 5.98, marking an increase of 4.62.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 20. It has decreased from 103.24 (Mar 24) to 9.48, marking a decrease of 93.76.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 20. It has decreased from 17.34 (Mar 24) to 6.58, marking a decrease of 10.76.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.52. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.52, marking an increase of 93.76.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.42. This value exceeds the healthy maximum of 70. It has increased from 82.66 (Mar 24) to 93.42, marking an increase of 10.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.56 (Mar 24) to 5.12, marking an increase of 1.56.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 1.80 (Mar 24) to 2.99, marking an increase of 1.19.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,436.46. It has increased from 11,426.80 (Mar 24) to 15,436.46, marking an increase of 4,009.66.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 2.13, marking an increase of 0.43.
- For EV / EBITDA (X), as of Mar 25, the value is 12.54. This value is within the healthy range. It has increased from 11.79 (Mar 24) to 12.54, marking an increase of 0.75.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For Retention Ratios (%), as of Mar 25, the value is 90.51. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.51, marking an increase of 93.75.
- For Price / BV (X), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 2.25, marking an increase of 0.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jubilant Pharmova Ltd:
- Net Profit Margin: 11.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.13% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.41% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.99
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.5 (Industry average Stock P/E: 50.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Bhartiagram, Amroha District Uttar Pradesh 244223 | investors@jubl.com http://www.jubilantpharmova.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shyam S Bhartia | Chairman |
| Mr. Hari S Bhartia | Co-Chairman |
| Mr. Priyavrat Bhartia | Managing Director |
| Mr. Arjun Shanker Bhartia | Joint Managing Director |
| Mr. Arvind Chokhany | WholeTime Director & Group CFO |
| Dr. Ramakrishnan Arul | Whole Time Director |
| Dr. Harsh Mahajan | Independent Director |
| Mr. Arun Seth | Independent Director |
| Mr. Vivek Mehra | Independent Director |
| Ms. Shivpriya Nanda | Independent Director |
| Mr. Shirish G Belapure | Independent Director |
| Mr. Sushil Kumar Roongta | Independent Director |
FAQ
What is the intrinsic value of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd's intrinsic value (as of 24 October 2025) is 1130.90 which is 1.15% lower the current market price of 1,144.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 18,219 Cr. market cap, FY2025-2026 high/low of 1,310/802, reserves of ₹6,239 Cr, and liabilities of 12,584 Cr.
What is the Market Cap of Jubilant Pharmova Ltd?
The Market Cap of Jubilant Pharmova Ltd is 18,219 Cr..
What is the current Stock Price of Jubilant Pharmova Ltd as on 24 October 2025?
The current stock price of Jubilant Pharmova Ltd as on 24 October 2025 is 1,144.
What is the High / Low of Jubilant Pharmova Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jubilant Pharmova Ltd stocks is 1,310/802.
What is the Stock P/E of Jubilant Pharmova Ltd?
The Stock P/E of Jubilant Pharmova Ltd is 37.5.
What is the Book Value of Jubilant Pharmova Ltd?
The Book Value of Jubilant Pharmova Ltd is 393.
What is the Dividend Yield of Jubilant Pharmova Ltd?
The Dividend Yield of Jubilant Pharmova Ltd is 0.44 %.
What is the ROCE of Jubilant Pharmova Ltd?
The ROCE of Jubilant Pharmova Ltd is 9.54 %.
What is the ROE of Jubilant Pharmova Ltd?
The ROE of Jubilant Pharmova Ltd is 9.55 %.
What is the Face Value of Jubilant Pharmova Ltd?
The Face Value of Jubilant Pharmova Ltd is 1.00.